226 related articles for article (PubMed ID: 27261537)
1. Pharmacogenetics of dabigatran etexilate interindividual variability.
Dimatteo C; D'Andrea G; Vecchione G; Paoletti O; Cappucci F; Tiscia GL; Buono M; Grandone E; Testa S; Margaglione M
Thromb Res; 2016 Aug; 144():1-5. PubMed ID: 27261537
[TBL] [Abstract][Full Text] [Related]
2. The Distribution of the Genotypes of
Abdrakhmanov A; Akilzhanova A; Shaimerdinova A; Zhalbinova M; Tuyakova G; Abildinova S; Albayev R; Ainabekova B; Chinybayeva A; Suleimen Z; Bekbossynova M
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372371
[TBL] [Abstract][Full Text] [Related]
3. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease.
Sychev D; Skripka A; Ryzhikova K; Bochkov P; Shevchenko R; Krupenin P; Ivashchenko D; Kogay V; Listratov A; Krainyaya A; Gurinovich O; Sokolova A; Napalkov D; Fomin V
Drug Metab Pers Ther; 2020 Mar; 35(1):. PubMed ID: 32134727
[TBL] [Abstract][Full Text] [Related]
4. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation.
Ji Q; Zhang C; Xu Q; Wang Z; Li X; Lv Q
Br J Clin Pharmacol; 2021 May; 87(5):2247-2255. PubMed ID: 33179295
[TBL] [Abstract][Full Text] [Related]
5. The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation.
Zhu Z; Qian C; Su C; Tao H; Mao J; Guo Z; Zhu X; Pan J
BMC Cardiovasc Disord; 2022 Nov; 22(1):481. PubMed ID: 36368930
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.
Shi J; Wang X; Nguyen JH; Bleske BE; Liang Y; Liu L; Zhu HJ
Biochem Pharmacol; 2016 Nov; 119():76-84. PubMed ID: 27614009
[TBL] [Abstract][Full Text] [Related]
7. Role of
Cumitini L; Renda G; Giordano M; Rolla R; Shail T; Sacchetti S; Iezzi L; Giacomini L; Zanotti V; Auciello R; Angilletta I; Foglietta M; Zucchelli M; Antonucci I; Stuppia L; Gallina S; Dianzani U; Patti G
J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731074
[No Abstract] [Full Text] [Related]
8. Genetic determinants of dabigatran plasma levels and their relation to bleeding.
Paré G; Eriksson N; Lehr T; Connolly S; Eikelboom J; Ezekowitz MD; Axelsson T; Haertter S; Oldgren J; Reilly P; Siegbahn A; Syvanen AC; Wadelius C; Wadelius M; Zimdahl-Gelling H; Yusuf S; Wallentin L
Circulation; 2013 Apr; 127(13):1404-12. PubMed ID: 23467860
[TBL] [Abstract][Full Text] [Related]
9. The impact of
Sychev DA; Levanov AN; Shelekhova TV; Bochkov PO; Denisenko NP; Ryzhikova KA; Mirzaev KB; Grishina EA; Gavrilov MA; Ramenskaya GV; Kozlov AV; Bogoslovsky T
Pharmgenomics Pers Med; 2018; 11():127-137. PubMed ID: 30100750
[TBL] [Abstract][Full Text] [Related]
10. The Effect of ABCB1 and CES1 Polymorphisms on Plasma Levels of Dabigatran and Risk of Hemorrhagic Complications in Ischemic Stroke Patients.
Anna O; Petr J; Hana M; Tereza Š; Petra K; Silvia K; Vlastimil Š; Hana H; Martin Š; Ivana Š; Jaroslava PS; Kateřina B; Jan M; Václav M; Aleš T
Am J Ther; 2024 Mar; ():. PubMed ID: 38525959
[TBL] [Abstract][Full Text] [Related]
11. Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran.
Zubiaur P; Saiz-Rodríguez M; Ochoa D; Navares-Gómez M; Mejía G; Román M; Koller D; Soria-Chacartegui P; Almenara S; Abad-Santos F
Adv Ther; 2020 Aug; 37(8):3537-3550. PubMed ID: 32564268
[TBL] [Abstract][Full Text] [Related]
12. The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects.
Liu Y; Yang C; Qi W; Pei Z; Xue W; Zhu H; Dong M; Guo Y; Cong D; Wang F
Pharmgenomics Pers Med; 2021; 14():477-485. PubMed ID: 33935512
[TBL] [Abstract][Full Text] [Related]
13. Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillation.
Šinigoj P; Malmström RE; Vene N; Rönquist-Nii Y; Božič-Mijovski M; Pohanka A; Antovic JP; Mavri A
Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):323-9. PubMed ID: 25981948
[TBL] [Abstract][Full Text] [Related]
14. Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report.
Wu T; Xia X; Fu J; Chen W; Zhang J
Medicine (Baltimore); 2020 Sep; 99(36):e22084. PubMed ID: 32899083
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation.
Tomita H; Araki T; Kadokami T; Yamada S; Nakamura R; Imamura Y; Fukuyama T; Nagano D; Hashimoto T; Uematsu A; Hosokawa K; Yamamoto K; Ueda S; Ando S;
Thromb Res; 2016 Sep; 145():100-6. PubMed ID: 27526389
[TBL] [Abstract][Full Text] [Related]
16. A novel coagulation parameter monitoring bleeding tendency of Chinese nonvalvular atrial fibrillation patients prescribing dabigatran etexilate.
Wang H; Zhou Y; Rong G; Lu L; Zhang J
Blood Coagul Fibrinolysis; 2016 Jul; 27(5):563-7. PubMed ID: 26881855
[TBL] [Abstract][Full Text] [Related]
17. Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment.
Taune V; Wallén H; Ågren A; Gryfelt G; Sjövik C; Wintler AM; Malmström RE; Wikman A; Skeppholm M
Thromb Res; 2017 May; 153():76-82. PubMed ID: 28347811
[TBL] [Abstract][Full Text] [Related]
18. Real life dabigatran and metabolite concentrations, focused on inter-patient variability and assay differences in patients with atrial fibrillation.
Boonen K; Schmitz E; Rozestraten F; van den Heuvel D; Brunsveld L; van der Voort P; van de Kerkhof D
Clin Chem Lab Med; 2017 Oct; 55(12):2002-2009. PubMed ID: 28328523
[TBL] [Abstract][Full Text] [Related]
19. Real-world variability in dabigatran levels in patients with atrial fibrillation.
Chan NC; Coppens M; Hirsh J; Ginsberg JS; Weitz JI; Vanassche T; Douketis JD; Schulman S; Eikelboom JW
J Thromb Haemost; 2015 Mar; 13(3):353-9. PubMed ID: 25523236
[TBL] [Abstract][Full Text] [Related]
20. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Reilly PA; Lehr T; Haertter S; Connolly SJ; Yusuf S; Eikelboom JW; Ezekowitz MD; Nehmiz G; Wang S; Wallentin L;
J Am Coll Cardiol; 2014 Feb; 63(4):321-8. PubMed ID: 24076487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
